Haleon Expects Further Growth After Profit Rises

Haleon, the global consumer health company, has reported a strong set of results for the full year 2024, with adjusted operating profit rising to £2.5 billion, a 10.8% increase from the previous year. The company's revenue grew by 5.0% to £11.2 billion, driven by organic revenue growth of 9.8% and a 10% increase in total dividend per ordinary share. Haleon's CEO, Brian McNamara, expressed satisfaction with the company's performance, highlighting the strength and appeal of its brands, with 71% of the business gaining or maintaining market share.

Haleon's strategic initiatives, such as increasing household penetration, maximizing innovation growth opportunities across categories, and maintaining strong execution and financial discipline, have contributed to the company's success. The company's focus on innovation has led to successful product launches, such as Sensodyne Clinical White, which became the #1 innovation in the US Oral Health market. Haleon's strong brand portfolio and consumer focus position the company well for continued growth and profitability in the future.



Looking ahead, Haleon expects further growth, with guidance for organic revenue growth of 4-6% in 2025. The company plans to invest in its global research and development center in Richmond, US, aiming to boost its pipeline for new product innovation. Haleon also plans to allocate funds for share buybacks in 2025, demonstrating the company's confidence in its future prospects.



In conclusion, Haleon's strong performance in 2024, driven by its strategic initiatives and innovation, positions the company well for continued growth and profitability. With a focus on increasing household penetration, maximizing innovation growth opportunities, and maintaining strong execution and financial discipline, Haleon is well-placed to deliver on its growth expectations in the coming years. Investors should consider Haleon as a strong investment opportunity in the consumer health sector.